TP53 and renal cell carcinoma: The study further suggested the colocalization of JMJD6 with p53 in the nucleus, upregulating p53 and its downstream effectors.204 SKLB325 also sensitizes renal cell carcinoma cells to sunitinib and works synergistically with sunitinib in inhibiting RCC growth.422 Recently, a research team performed molecular docking and retrieved a new JMJD6 inhibiting compound J2, the optimization of which yielded a more potent JMJD6 inhibitor 7p.